HIV阳性宫颈癌的研究进展  

Research Progress in HIV-Positive Cervical Cancer Patients

作　　者：李岚[1] 代佩灵 吴星娆[1] 张岚 Li Lan;Dai Peiling;Wu Xingrao;Zhang Lan(Department of Radiation Oncology,Yunnan Cancer Hospital&the Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center,Kunming 650118,Yunnan,China)

机构地区：[1]云南省肿瘤医院,云南省癌症中心,昆明医科大学第三附属医院放疗科,昆明650118

出　　处：《肿瘤预防与治疗》2021年第8期763-768,共6页Journal of Cancer Control And Treatment

基　　金：国家自然科学基金(编号:81802614);华南肿瘤学国家重点实验室开放课题(编号:KY012294);云南省卫生健康委员会医学后备人才(编号:H-2018003);云南省基础研究青年项目(编号:2019FD090);云南省科技计划研究项目[编号:2019FE001(-151)]。

摘　　要：宫颈癌是人免疫缺陷病毒(human immunoduficiency virus,HIV)感染人群最常见的恶性肿瘤之一,被称为HIV感染相关肿瘤。相比一般人群,HIV阳性宫颈癌发病年龄早、肿瘤分期晚、治疗难度大。在控制病毒及抗肿瘤联合治疗过程中存在治疗完成度低、远期疗效欠佳等难题。本文拟对HIV阳性宫颈癌的发病、预防、治疗及预后的研究现状及进展进行全面综述以更好指导临床治疗。Cervical cancer is one of the most common cancers in human immunodeficiency virus(HIV)-infected women,and is considered to be HIV-related malignancy.Compared with the general population,HIV-positive women with cervical cancer are substantially younger,in later tumor stages and poorer nutritional status,making it difficult to complete treatment in the anti-tumor and anti-virus process and achieve an acceptable survival.This review focuses on current status and progress of studies on the incidence,prevention,treatment and prognosis of HIV-positive cervical cancer patients to better guide the clinical treatment.

关 键 词：人类免疫缺陷病毒(HIV) 宫颈癌 预防 治疗 预后 

分 类 号：R737.33[医药卫生—肿瘤] R512.91[医药卫生—临床医学]